YFYan Feng

Yan Feng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yan Feng has a total of 142 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Quality-Adjusted Life Years (QALYs) in healthcare decision making

    by Esubalew Assefa, Yan Feng, Borislava Mihaylova

    What are QALYs and what role do QALYs play in deciding which treatments the NHS funds?

  • Open Access

    Tackling chronic depression, adapting and testing the DIALOG+ solution-focused approach for people with long-term depression: the TACK mixed-methods research programme

    by Victoria Bird, Philip McNamee, Neil Walker, Yan Feng, Mustapha Mohammed, Esubalew Assefa, Aleksandra Matanov, Lauren Jerome, Andrew Molodynski, Shonagh Scott, et al.

    Background: Long-term (previously termed chronic) depression is associated with significant personal, social and economic consequences often resulting in a poor quality of life for individuals. Effective treatments that improve quality of life for individuals with chronic depression remain limited. DIALOG+, a solution-focused and person-centred intervention, guided by a tablet-based application, was developed to address these challenges. Initially proven to be effective in handling psychotic disorders, this study adapted and evaluated DIALOG+ for individuals with chronic depression. Objectives: The research aimed to adapt and assess the feasibility, clinical and cost-effectiveness of DIALOG+ for improving quality of life, reducing depression severity and enhancing treatment satisfaction among individuals with chronic depression. Setting: The study was conducted across nine National Health Service sites in England, encompassing both urban and rural settings. Participants were recruited from outpatient Community Mental Health Teams, including primary care services, such as increasing access to psychological therapies, ensuring diverse sociodemographic characteristics and clinical contexts. Clinicians from varied professional backgrounds, including mental health nurses, psychiatrists and social workers, were trained to deliver the intervention. Design: The study comprised multiple interlinked work packages: Systematic review: existing recruitment and retention strategies for trials with individuals with depression. Focus groups and pilot study: to adapt the intervention. Small-scale cluster randomised controlled trial: testing feasibility of the intervention and trial processes. Large multisite pragmatic cluster randomised controlled trial: including a nested qualitative process evaluation and economic evaluation. Training and implementation study: evaluating feasibility and applicability within different clinical services. A total of 366 participants with chronic depression were included. Patients were clustered by clinician and clusters randomised 1 : 1 to receive DIALOG+ or an active control (treatment as usual with DIALOG scale completion). Participants were assessed at baseline, 3, 6 and 12 months. The primary outcome was subjective quality of life, measured by the Manchester Short Assessment of Quality of Life at 12 months. Secondary outcomes included depression severity (Montgomery–Åsberg Depression Rating Scale, Beck Depression Inventory-II), treatment satisfaction (Client Satisfaction Questionnaire-8) and health-related quality of life (EuroQol-5 Dimensions, five-level version). Economic evaluation was conducted from National Health Service and Personal Social Services perspectives. Process evaluation involved implementation data and interviews with participants and clinicians to assess intervention experience. Results: The systematic review highlighted the overall poor quality of reporting for existing trials of psychosocial intervention, with many trials failing to outline information on recruitment and retention. It was demonstrated that the intervention was feasible and acceptable to individuals with chronic depression during the feasibility and pilot work. Although the intervention remained unchanged, feedback from the initial phases of the project, alongside lived experience input led to changes in intervention training, which included the addition of case vignettes specific to long-term depression. Within the cluster randomised controlled trial, at 12 months, the DIALOG+ group exhibited a borderline significant improvement in Manchester Short Assessment of Quality of Life scores compared to the control group (adjusted mean difference: 0.18, p = 0.05). This equated to an average improvement of 1 point on 2 of the 12 Manchester Short Assessment of Quality of Life domains. There were no significant differences in any other outcome at 6 and 12 months. However, longitudinal analysis demonstrated significant reductions in Montgomery–Åsberg Depression Rating Scale and Beck Depression Inventory-II scores in the DIALOG+ group at 12 months ( p < 0.01), and participants reported better coping strategies and resilience in managing depressive symptoms. The intervention was associated with an incremental cost-effectiveness ratio of £4749 per quality-adjusted life-year gained. Probabilities of cost-effectiveness were 79.8% at a willingness-to-pay threshold of £20,000/quality-adjusted life-year and 87% at £30,000/quality-adjusted life-year. Despite high retention rates (73% at 12 months), challenges included attrition due to COVID-19 disruptions, with whole clusters lost during early lockdown phases. Fidelity to the intervention protocol varied, with just under a third of participants receiving fewer than three sessions (the minimum recommended dose). Nonetheless, the observed treatment effects were robust across varying levels of engagement. Findings from the process evaluation were increased satisfaction with care, improved therapeutic relationships and a greater sense of empowerment. However, some participants noted challenges with the structured nature of the intervention and the use of technology. This was mirrored by the clinician experience, which found DIALOG+ easy to integrate into routine care and appreciated its structured, patient-centred approach. Barriers included variability in implementation fidelity and technological challenges, particularly during remote delivery. Limitations: Key challenges across the programme included: (1) disruption from the COVID-19 pandemic, leading to adaptations in delivery methods and pauses in recruitment; (2) implementation variability, with some clinicians requiring additional training to maintain fidelity within the cluster randomised controlled trial; and (3) attrition and missing data, particularly in measures for economic evaluation, which necessitated the use of multiple imputation for some analyses. Conclusions: The DIALOG+ demonstrated small but clinically meaningful improvements in quality of life and reductions in depression severity for individuals with chronic depression. While the improvement in Manchester Short Assessment of Quality of Life scores was very modest, it represents a potential gain for a population with long-term difficulties and low baseline quality of life. The probabilities of the intervention being cost-effective in comparison to active control at the National Institute for Health and Care Excellence recommended willingness-to-pay thresholds were high. The intervention was also associated with high patient and clinician satisfaction. These findings support the wider implementation of DIALOG+ in routine mental health care, with adaptations for remote delivery and ongoing support for clinicians. Future directions: Further research is needed to explore the long-term impacts of DIALOG+ on quality of life and depression severity. Peer-delivered models and strategies to enhance engagement with the intervention may strengthen its effectiveness and scalability. Trial registration: This trial is registered as ISRCTN16864442. The definitive cRCT was registered as ISRCTN11301686. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Programme Grants for Applied Research Programme (NIHR award ref: RP-PG-0615-20010) and is published in full in Programme Grants for Applied Research ; Vol. 14, No. 20. See the NIHR Funding and Awards website for further award information.

  • Open Access

    Assessing measurement properties of EQ-5D-5L and ICECAP-A in patients with chronic depression in England

    by Esubalew Assefa, Victoria Bird, Stefan Priebe, Philip McNamee, Yan Feng

    EQ-5D and ICECAP-A instruments are widely used as outcome measures in economic evaluation. This study aimed to evaluate the validity and responsiveness of EQ-5D-5L and ICECAP-A for economic evaluation in patients with chronic depression in England. Data from 365 patients with chronic depression who took part in a cluster randomised controlled trial were used. The EQ-5D-5L, ICECAP-A and four additional outcome measures (MANSA, BDI-II, MADRS and CGI-S) were administrated at baseline and 12-months post-randomisation. We assessed the floor/ceiling effect, structural validity, convergent validity, known-group validity, and responsiveness of EQ-5D-5L and ICECAP-A in this population. Exploratory factor analysis with pooled EQ-5D-5L and ICECAP-A items suggested a two-factor solution (i.e. psychosocial wellbeing and physical functioning factors). The EQ-5D-5L index and ICECAP-A index were positively correlated with each other (ρ = 0.578, p < 0.001). The two measures correlated the strongest with the BDI-II, and the weakest with CGI-S. Both EQ-5D-5L index and ICECAP-A index showed good discriminative ability. Mental health condition specific measures (BDI-II, MADRS and CGI-S) and a subjective quality of life measure (MANSA) reported better responsiveness than EQ-5D-5L index and ICECAP-A index. The ICECAP-A index reported better responsiveness than the EQ-5D-5L index. The responsiveness of the EQ-5D-5L was largely driven by the anxiety/depression dimension, followed by the usual activities dimension. For the ICECAP-A, four attributes of the instrument reported good responsiveness except for the autonomy attribute. EQ-5D-5L and ICECAP-A showed good validity and responsiveness among patients with chronic depression in England. We recommend ICECAP-A as an outcome measure in economic evaluation for medical interventions that aim to improve the psychosocial wellbeing of adults with chronic depression for the instrument’s structural validity and its better responsiveness than the EQ-5D-5L. The trial was registered on 13/06/2019. The registration number is ISRCTN11301686.


  • Open Access

    Protocol of a randomised controlled trial of a novel brief psychological intervention for young people presenting to emergency departments in the UK with self-harm or suicidal ideation with recent self-harm: the SASH study (Supporting Adolescents with Self-Harm)

    by Rose McCabe, Sally O’kEeffe, Dennis Ougrin, Stefan Priebe, Peter Martin, Yan Feng, Rachel Temple, Maria Long

    Introduction Self-harm is the strongest predictor of suicide in young people. Self-harm presentations to the emergency department (ED) are associated with repeat self-harm and suicide. Rapid follow-up contact after ED offers an opportunity to intervene before self-harm becomes an established coping strategy. Despite recent progress in self-harm treatment, currently, there are no evidence-based interventions to prevent future self-harm and suicide offered to young people after visits to the ED. Preliminary evidence suggests therapeutic assessment and rapid follow-up contacts may reduce self-harm and improve engagement in follow-up care. In this study, we assess the clinical and cost-effectiveness of a brief psychological intervention, supporting adolescents with self-harm (SASH), in addition to standard care in a randomised controlled trial, compared with standard care only. As per National Institute for Health and Care Excellence guidelines, standard care involves at least one follow-up by a mental health professional within 7 days of ED discharge. Methods and analysis The SASH intervention comprises up to six follow-up contacts with a mental health professional delivered over approximately 2 months for young people and their carers using a solution-focused approach, shortly after presenting to the ED. Participants are aged 12–18, presenting to the ED with self-harm or suicidal ideation (with self-harm in the past month), with capacity to consent. We aim to recruit 144 young people into the trial who will be randomised on a 1:1 basis to the SASH intervention or treatment as usual. Participants are assessed postintervention/standard care and at 6-month follow-up after randomisation. Self-reported self-harm is assessed via text message survey every 2 weeks during the 6-month follow-up period. The primary outcome is self-reported episodes of self-harm in the past month assessed at 6 months by summing three behavioural domains of the self-injurious thoughts and behaviours interview. We hypothesise that the therapeutic relationship with the mental health practitioner will mediate this relationship. Secondary outcomes include symptoms of depression and anxiety, frequency of reattendance at ED, death by suicide, school attendance, well-being and additional domains of self-harm-related behaviour and thoughts in the past month. The trial will also consider service use, costs to carer and carer health-related quality of life to evaluate the costs and cost-effectiveness of the intervention. Ethics and dissemination London-Riverside Nation Health Service REC (22/LO/0400) provided a favourable ethical opinion. Findings will be disseminated through social media, a website, scientific papers, conferences and reports, in collaboration with our Young Person’s Lived Experience Advisory Group. Trial registration number ISRCTN81846131. Protocol version 13.0, 30.06.2025.


  • Open Access

    Implementing bedside electronic transfusion checks at Barts Health NHS Trust: A study protocol for evaluating the effectiveness and value for money

    by Montasir Ahmed, Laura Green, Iram Bhatti, Catherine Booth, Louise Bowles, Ollie Djurdjevic, Helinor McAleese, Josephine McCullagh, Michael F. Murphy, Florence Oyekan, et al.

    Objective: To evaluate the benefits of implementing Bedside Electronic Transfusion Checks (BETC) to patients and value for money at four hospitals at Barts Health NHS Trust.Background: BETC aims to enhance transfusion safety by reducing errors associated with positive patient identification checks for compatibility, blood sample labelling, and blood component administration. There is limited evidence on the potential benefits to patients and healthcare professionals as well as value for money for implementing BETC.Methods: The BETC implementation at four hospitals adopted a non‐randomised, staggered, multi‐phase strategy. Alongside the implementation, an evaluation study was conducted. The intervention consists of a portable handheld scanning device and a mobile printer used for printing labels that are attached to the compatibility blood bottles and for verifying the patient's details against blood units prior to blood administration. Eligible patients are those who received blood transfusions or had compatibility tests performed during the evaluation period. The outcomes for evaluation include transfusion‐related errors and cost savings from an NHS perspective. Regression‐based time‐series intervention analyses will be applied to evaluate the impacts of BETC implementation.Expected Results: The three‐year evaluation includes a 12‐month pre‐implementation period (May 2022 to April 2023) and a 24‐month implementation period (May 2023 to April 2025). All staff involved with bedside transfusion were trained on the new system. Data were collected from different transfusion datasets, process mapping dataset, and Health Economics Inventory dataset.Discussion: Findings from this evaluation study will provide empirical evidence on the effectiveness and value for money of implementing BETC and will support decision‐making for its wider roll‐out in the UK.


  • Open Access

    Heterogeneous association of health with patient and general practice characteristics by region, age and chronic condition: pooled cross-sectional study of patient-level data from England

    by Yan Feng, Hugh Gravelle, Vladimir Sergeevich Gordeev

    Objectives: To investigate the association of individual patient health with their characteristics, including income deprivation, ethnicity and gender, with the size, quality and staffing of their general practices, and how these associations and income-related health inequality vary across chronic conditions, regions and age bands. Design: Using observational pooled cross-sectional individual patient survey data linked with data on general practice clinical quality and staffing and deprivation at Lower-Layer Super Output Area level. Ordinary least-squares multiple regression models of patient health estimated on the full sample and on eight condition-specific, nine region-specific and six age-specific subsamples. Three concentration indices embodying different value judgements summarise income-related health inequality in the full sample and subsamples. Setting: Primary care in England. Participants: Over 1 million adult patients in 6426 general practices in 2015/2016 and 2016/2017. Primary outcome measures: Patient-reported health (the 5-level EQ-5D version or EQ-5D-5L). Results: Patients who are younger, male, more satisfied with their practice, have fewer chronic conditions and live in less-income or education-deprived areas report better health. White ethnicity is associated with worse health up to age 64 and better health from age 65, with better health in five of the eight chronic condition samples, and in the regional samples except for London and Yorkshire and Humber regions. Practice clinical quality is positively associated with health in the full sample but only in 4 of the 23 subsamples. Income-related health inequality is worst for patients with a mental health problem, residents in the northwest and northeast regions and is greatest for those aged 55–64. The three concentration indices are highly positively correlated across chronic condition and age-band samples. One index has a much weaker correlation relationship with the other two indices in the region-specific samples. Conclusion: Income-related health inequality and the associations of health with patient and practice characteristics are heterogeneous by patients’ chronic condition, age and region.

  • Open Access

    Quality Appraisal in Systematic Literature Reviews of Studies Eliciting Health State Utility Values: Conceptual Considerations

    by Muchandifunga Trust Muchadeyi, Karla Hernandez-Villafuerte, Gian Luca Di Tanna, Rachel D. Eckford, Yan Feng, Michela Meregaglia, Tessa Peasgood, Stavros Petrou, Jasper Ubels, Michael Schlander

    Background The increasing number of studies that generate health state utility values (HSUVs) and the impact of HSUVs on cost-utility analyses make a robust tailored quality appraisal (QA) tool for systematic reviews of these studies necessary. Objective This study aimed to address conceptual issues regarding QA in systematic reviews of studies eliciting HSUVs by establishing a consensus on the definitions, dimensions and scope of a QA tool specific to this context. Methods A modified Delphi method was used in this study. An international multidisciplinary panel of seven experts was purposively assembled. The experts engaged in two anonymous online survey rounds. After each round, the experts received structured and controlled feedback on the previous phase. Controlled feedback allowed the experts to re-evaluate and adjust their positions based on collective insights. Following these surveys, a virtual face-to-face meeting was held to resolve outstanding issues. Consensus was defined a priori at all stages of the modified Delphi process. Results The response rates to the first-round and second-round questionnaires and the virtual consensus meeting were 100%, 86% and 71%, respectively. The entire process culminated in a consensus on the definitions of scientific quality, QA, the three QA dimensions—reporting, relevance and methodological quality—and the scope of a QA tool specific to studies that elicit HSUVs. Conclusions Achieving this consensus marks a pivotal step towards developing a QA tool specific to systematic reviews of studies eliciting HSUVs. Future research will build on this foundation, identify QA items, signalling questions and response options, and develop a QA tool specific to studies eliciting HSUVs.


  • Open Access

    Pay-for-Performance incentives for specialised services in England: a mixed methods evaluation

    by Yan Feng, Søren Rud Kristensen, Paula Lorgelly, Rachel Meacock, Alberto Núñez-Elvira, Marina Rodés-Sánchez, Luigi Siciliani, Matt Sutton

    Background: A Pay-for-Performance (P4P) programme, known as Prescribed Specialised Services Commissioning for Quality and Innovation (PSS CQUIN), was introduced for specialised services in the English NHS in 2013/2014. These services treat patients with rare and complex conditions. We evaluate the implementation of PSS CQUIN contracts between 2016/2017 and 2018/2019. Methods: We used a mixed methods evaluative approach. In the quantitative analysis, we used a difference-in-differences design to evaluate the effectiveness of ten PSS CQUIN schemes across a range of targeted outcomes. Potential selection bias was addressed using propensity score matching. We also estimated impacts on costs by scheme and financial year. In the qualitative analysis, we conducted semi-structured interviews and focus group discussions to gain insights into the complexities of contract design and programme implementation. Qualitative data analysis was based on the constant comparative method, inductively generating themes. Results: The ten PSS CQUIN schemes had limited impact on the targeted outcomes. A statistically significant improvement was found for only one scheme: in the clinical area of trauma, the incentive scheme increased the probability of being discharged from Adult Critical Care within four hours of being clinically ready by 7%. The limited impact may be due to the size of the incentive payments, the complexity of the schemes’ design, and issues around ownership, contracting and flexibility. Conclusion: The PSS CQUIN schemes had little or no impact on quality improvements in specialised services. Future P4P programmes in healthcare could benefit from lessons learnt from this study on incentive design and programme implementation.


  • Open Access

    Cost-effectiveness of implementing a digital psychosocial intervention for patients with psychotic spectrum disorders in low- and middle-income countries in Southeast Europe: economic evaluation alongside a cluster randomised trial

    by Y Feng, C Roukas, M Russo, S Repišti, A Džubur Kulenović, L Injac Stevović, J Konjufca, S Markovska-Simoska, Lj Novotni, I Ristić, et al.

    Background DIALOG+ is a digital psychosocial intervention aimed at making routine meetings between patients and clinicians therapeutically effective. This study aimed to evaluate the cost-effectiveness of implementing DIALOG+ treatment for patients with psychotic disorders in five low- and middle-income countries in Southeast Europe alongside a cluster randomised trial. Methods Resource use and quality of life data were collected alongside the multi-country cluster randomised trial of 468 participants with psychotic disorders. Due to COVID-19 interruptions of the trial's original 12-month intervention period, adjusted costs and quality-adjusted life years (QALYs) were estimated at the participant level using a mixed-effects model over the first 6 months only. We estimated the incremental cost-effectiveness ratio (ICER) with uncertainty presented using a cost-effectiveness plane and a cost-effectiveness acceptability curve. Seven sensitivity analyses were conducted to check the robustness of the findings. Results The average cost of delivering DIALOG+ was euro91.11 per participant. DIALOG+ was associated with an incremental health gain of 0.0032 QALYs (95% CI -0.0015, 0.0079), incremental costs of euro84.17 (95% CI -8.18, 176.52), and an estimated ICER of euro26,347.61. The probability of DIALOG+ being cost-effective against three times the weighted gross domestic product (GDP) per capita for the five participating countries was 18.9%. Conclusion Evidence from the cost-effectiveness analyses in this study suggested that DIALOG+ involved relatively low costs. However, it is not likely to be cost-effective in the five participating countries compared with standard care against a willingness-to-pay threshold of three times the weighted GDP per capita per QALY gained.


  • Open Access

    Clinical- and cost-effectiveness of a technology-supported and solution-focused intervention (DIALOG+) in treatment of patients with chronic depression—study protocol for a multi-site, cluster randomised controlled trial [TACK]

    by Philip McNamee, Aleksandra Matanov, Lauren Jerome, Sally Kerry, Neil Walker, Yan Feng, Andrew Molodynski, Shonagh Scott, Latha Guruvaiah, Sue Collinson, et al.

    Background: Many with an acute depressive disorder go on to develop chronic depression, despite ongoing care. There are few specifically designed interventions to treat chronic depression. DIALOG+, a technology-assisted intervention based on the principles of solution-focused therapy, may be beneficial. It has been shown to be effective as a treatment for patients with psychotic disorders, especially in regards to increasing quality of life. DIALOG+ was designed to be flexibly applied and not diagnosis-specific, aiming to structure communication and generate a personally-tailored care plan. This cluster randomised controlled trial (RCT) is part of a programme of research to adapt and test DIALOG+ for patients with chronic depression. Methods: Patients will be eligible for the trial, if they have exhibited symptoms of depression or non-psychotic low mood for at least 2 years, have regular contact with a clinician and have a low subjective quality of life and moderate depressive symptoms. Clinicians, who routinely see eligible patients, will be recruited from a number of sites across NHS England. Clusters will have between 1 and 6 patients per clinician and will be randomised in a 1:1 ratio to either the intervention (DIALOG+) or active control group (treatment as usual + DIALOG scale). Clinicians in the intervention group are trained and asked to deliver the intervention regularly for 12 months. Active control participants receive treatment as usual and are asked to rate their satisfaction with areas of life and treatment on the DIALOG scale at the end of the clinical session. Approximately 112 clinician clusters will be recruited to reach a total patient sample size of 376. Clinical and social outcomes including costs are assessed at baseline and 3, 6 and 12 months post randomisation. The primary outcome will be subjective quality of life at 12 months. Discussion: This definitive multi-site, cluster RCT aims to evaluate the clinical- and cost-effectiveness of DIALOG+ for people with chronic depression. If shown to be effective for this patient population it could be used to improve outcomes of mental health care on a larger scale, ensuring that patients with complex and co-morbid diagnoses can benefit. Trial registration: ISRCTN11301686. Registered on 13 Jun 2019.